{"id":"dalfopristin","rwe":[{"pmid":"41900471","year":"2026","title":"One Health Investigation of Stage-Dependent Antimicrobial Resistance Patterns Across Intermediate and Ripened Dairy Matrices: The Tyrovolia-Kopanisti Paradigm.","finding":"","journal":"Microorganisms","studyType":"Clinical Study"},{"pmid":"41754396","year":"2026","title":"Phenotypic and Molecular Characterization of Clinical Isolates of Vancomycin-Resistant Enterococcus faecium in the Health District of Bolzano (Italy) During 2021-2023.","finding":"","journal":"Pathogens (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41751058","year":"2026","title":"Antimicrobial Resistance in Indicator Microorganisms Escherichia coli and Enterococcus spp. from Healthy Dairy Cattle in Latvia.","finding":"","journal":"Animals : an open access journal from MDPI","studyType":"Clinical Study"},{"pmid":"41516125","year":"2025","title":"Prophage φEr670 and Genomic Island GI_Er147 as Carriers of Resistance Genes in Erysipelothrix rhusiopathiae Strains.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41422141","year":"2025","title":"Prevalence and antimicrobial susceptibility of multi drug-resistant bacteria isolates in adult intensive care units: a six-year retrospective study from a tertiary hospital in Mogadishu, Somalia.","finding":"","journal":"BMC infectious diseases","studyType":"Clinical Study"}],"tags":[{"label":"Streptogramin Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01FG02","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Complicated Skin and Skin Structure Staphylococcus Aureus Infection","category":"indication"},{"label":"Streptococcus pyogenes infection","category":"indication"},{"label":"Vancomycin resistant enterococcus","category":"indication"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[],"contraindications":["Disease of liver","Hyperbilirubinemia","Pseudomembranous enterocolitis"],"specialPopulations":{"Pregnancy":"Pregnancy. Teratogenic Effects. Reproductive studies have been performed in mice at doses up to 40 mg/kg/day (approximately half the human dose based on body-surface area), in rats at doses up to 120 mg/kg/day (approximately 2.5 times the human dose based on body-surface area), and in rabbits at doses up to 12 mg/kg/day (approximately half the human dose based on body-surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to Synercid.There are, however, no adequate","Geriatric use":"In phase comparative trials of Synercid, 37% of patients (n=404) were >=65 years of age, of which 145 were >=75 years of age. In the phase non-comparative trials, 29% of patients (n=346) were >=65 years of age, of which 112 were >=75 years of age. There were no apparent differences in the frequency, type, or severity of related adverse reactions including cardiovascular events between elderly and younger individuals.","Paediatric use":"Synercid has been used in limited number of pediatric patients under emergency-use conditions at dose of 7.5 mg/kg q8h or q12h. However, the safety and effectiveness of Synercid in patients under 16 years of age have not been established."}},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DALFOPRISTIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:35:48.907790+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:35:53.485981+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DALFOPRISTIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:35:53.847818+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial 70S ribosome inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:54.891678+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200937/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:54.547889+00:00"}},"allNames":"synercid","offLabel":[],"synonyms":["dalfopristin mesilate","dalfopristin","dalfopristin mesylate","RP-54476"],"timeline":[{"date":"1999-09-21","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Synercid (DALFOPRISTIN) is a Streptogramin Antibacterial drug, originally developed by Rhône-Poulenc Rorer and currently owned by Pfizer. It is a small molecule modality, approved by the FDA in 1999 for treating complicated skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes, and Vancomycin-resistant enterococcus. Synercid works by inhibiting protein synthesis in bacteria, ultimately leading to cell death. It has a short half-life of 0.74 hours. Synercid is a patented drug, and its commercial status is not generic.","approvals":[{"date":"1999-09-21","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Synercid","ecosystem":[{"indication":"Complicated Skin and Skin Structure Staphylococcus Aureus Infection","otherDrugs":[{"name":"daptomycin","slug":"daptomycin","company":"Cubist"},{"name":"ertapenem","slug":"ertapenem","company":"Merck Sharp Dohme"},{"name":"levofloxacin","slug":"levofloxacin","company":"Janssen Pharms"},{"name":"linezolid","slug":"linezolid","company":"Pharmacia And Upjohn"}],"globalPrevalence":null},{"indication":"Streptococcus pyogenes infection","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"benzathine benzylpenicillin","slug":"benzathine-benzylpenicillin","company":"King Pharms"},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Vancomycin resistant enterococcus","otherDrugs":[{"name":"linezolid","slug":"linezolid","company":"Pharmacia And Upjohn"},{"name":"quinupristin","slug":"quinupristin","company":""}],"globalPrevalence":null}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"Streptogramin Antibacterial","explanation":"","oneSentence":"","technicalDetail":"Synercid binds to the 50S subunit of the bacterial ribosome, specifically targeting the P site, which is responsible for peptide bond formation. This inhibition of protein synthesis leads to a decrease in bacterial growth and ultimately cell death."},"commercial":{"launchDate":"1999","_launchSource":"DrugCentral (FDA 1999-09-21, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/778","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DALFOPRISTIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DALFOPRISTIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:28:01.089658","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:36:01.229820+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"quinupristin","drugSlug":"quinupristin","fdaApproval":"1999-09-21","relationship":"same-class"}],"genericName":"dalfopristin","indications":{"approved":[{"name":"Complicated Skin and Skin Structure Staphylococcus Aureus Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults"},{"name":"Streptococcus pyogenes infection","source":"DrugCentral","snomedId":302809008,"regulator":"FDA","eligibility":"Adults"},{"name":"Vancomycin resistant enterococcus","source":"DrugCentral","snomedId":113727004,"regulator":"FDA","eligibility":"Not specified"}],"offLabel":[{"name":"Pyrexia of unknown origin","source":"DrugCentral","drugName":"DALFOPRISTIN","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"quinupristin","brandName":"quinupristin","genericName":"quinupristin","approvalYear":"1999","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT00240747","phase":"PHASE3","title":"Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2000-06","conditions":["Gram-Positive Bacterial Infections"],"enrollment":0,"completionDate":"2005-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Synercid"}]},"crossReferences":{"NUI":"N0000179689","MMSL":"8300","NDDF":"007888","UNII":"R9M4FJE48E","VUID":"4021183","CHEBI":"CHEBI:4309","VANDF":"4021183","INN_ID":"6581","RXNORM":"229369","UMLSCUI":"C0756085","chemblId":"CHEMBL1200937","ChEMBL_ID":"CHEMBL1200937","KEGG_DRUG":"D00853","DRUGBANK_ID":"DB01764","PDB_CHEM_ID":" DOL","PUBCHEM_CID":"6323289","SNOMEDCT_US":"116111008","IUPHAR_LIGAND_ID":"10797","MESH_SUPPLEMENTAL_RECORD_UI":"C113826"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.74 hours","clearance":"16.0 mL/min/kg","fractionUnbound":"0.82%","volumeOfDistribution":"0.39 L/kg"},"publicationCount":1216,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"J01FG02","allCodes":["J01FG02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 22","pmid":"41900471","title":"One Health Investigation of Stage-Dependent Antimicrobial Resistance Patterns Across Intermediate and Ripened Dairy Matrices: The Tyrovolia-Kopanisti Paradigm.","journal":"Microorganisms"},{"date":"2026 Jan 28","pmid":"41754396","title":"Phenotypic and Molecular Characterization of Clinical Isolates of Vancomycin-Resistant Enterococcus faecium in the Health District of Bolzano (Italy) During 2021-2023.","journal":"Pathogens (Basel, Switzerland)"},{"date":"2026 Feb 13","pmid":"41751058","title":"Antimicrobial Resistance in Indicator Microorganisms Escherichia coli and Enterococcus spp. from Healthy Dairy Cattle in Latvia.","journal":"Animals : an open access journal from MDPI"},{"date":"2025 Dec 25","pmid":"41516125","title":"Prophage φEr670 and Genomic Island GI_Er147 as Carriers of Resistance Genes in Erysipelothrix rhusiopathiae Strains.","journal":"International journal of molecular sciences"},{"date":"2025 Dec 20","pmid":"41422141","title":"Prevalence and antimicrobial susceptibility of multi drug-resistant bacteria isolates in adult intensive care units: a six-year retrospective study from a tertiary hospital in Mogadishu, Somalia.","journal":"BMC infectious diseases"}],"combinationProducts":[{"brandName":"Synercid","ingredients":"dalfopristin + quinupristin"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1999","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-09-21T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-09-21T00:00:00.000Z","mah":"KING PHARMS","brand_name_local":"SYNERCID","application_number":"NDA050747"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-09-21T00:00:00.000Z","mah":"KING PHARMS","brand_name_local":"SYNERCID","application_number":"NDA050748"},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:36:01.229820+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}